Coherus BioSciences announced that it has been issued a complete response letter by the FDA in response to its biologics license application for CHS-1701, a pegfilgrastim biosimilar candidate.
Coherus BioSciences announced yesterday that it has been issued a complete response letter by the FDA in response to its biologics license application for CHS-1701, a pegfilgrastim biosimilar candidate referenced on Amgen’s Neulasta, a product that Coherus called the largest-selling oncology biologic in the United States.
In its letter, the agency asked Coherus to perform a reanalysis of a subset of samples with a revised immunogenicity assay and to provide additional manufacturing-related process information. The FDA did not request a clinical study of CHS-1701 in oncology patients, however, and did not indicate that additional process qualification lots would be necessary.
Coherus says that it will work with the agency to address its outstanding concerns. President and CEO of Coherus BioSciences, Denny Lanfear, said, “While we are disappointed in the delay that this additional request has caused, we remain confident in our ability to address the FDA’s request for the purpose of obtaining approval for CHS-1701. We are encouraged that a patient study has not been requested and we expect that we will be able to respond to the FDA and meet with them to define a path forward in the coming months…we anticipate that CHS-1701’s approval will generate significant US healthcare savings while increasing patient access.”
Investors in Coherus may feel less confident than Lanfear, however; after news of the FDA’s letter broke, the company’s stock prices dropped by 27.2% in Monday’s midday trading.
News of this latest biosimilar setback comes just 5 months after Sandoz withdrew its pegfilgrastim product from consideration by the European Medicines Agency after being issued a list of questions by the agency’s Committee for Medicinal Products for Human Use. Sandoz had previously received its own complete response letter from the FDA for the same product.
In the coming months, all industry eyes will be on Mylan and Biocon’s attempt at a pegfilgrastim biosimilar, MYL-1401H. The FDA accepted a Biologics License Application from Mylan in February, and the agency’s goal date set under the Biosimilar User Fee Act is October 9 of this year.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.